97258 ⎘
Immunoglobulins specific features characterized by taxonomic origin
Sub-classes:IMMUNOLOGIC AGENT AGAINST CANINE MALIGNANCY
#2CANINE ANTIBODY MUTANTS
#3Antibodies to Symmetrically Dimethylated Arginine Analytes and Use Thereof
#4EQUINE ANTIBODY MUTANTS
#5COMPLEMENT C4D ASSAY
#6ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF
#7COMPOSITIONS AND METHODS FOR OPTIMIZED IGG PRODUCTION
#8CHO HOST CELL PROTEIN ASSAY
#9VL ANTIGEN BINDING PROTEINS EXHIBITING DISTINCT BINDING CHARACTERISTICS
#10ANTIBODY AND USE THEREOF
#11CANINIZED ANTIBODIES TO HUMAN NGF
#12CANINE ANTIBODY LIBRARIES
#13UNGULATE-DERIVED POLYCLONAL IMMUNOGLOBULIN SPECIFIC FOR INFLUENZA VIRUS AND USES THEREOF
#14BISPECIFIC ANTIBODY FOR MEMBRANE CLEARANCE OF TARGET RECEPTORS
#15PHOSPHO-TAU ANTIBODIES AND METHODS OF USE
#16AGENT, USES AND METHODS FOR TREATMENT
#17ANTIBODIES AND METHODS TARGETING INTERLEUKIN-19
#18A Method for Producing a Recombinant Allotypespecific Rabbit Monoclonal Antibody
#19ANTIGEN BINDING MOLECULES AND METHODS OF USE THEREOF
#20ANTI-LAG-3 ANTIBODIES AND METHODS OF USE THEREOF
#21ANTIBODIES AND IgG FUSION PROTEINS WITH AN EXTENDED HALF-LIFE
#22CANINE MONOCLONAL ANTIBODIES AGAINST CANINE CYTOTOXIC T LYMPHOCYTE ASSOCIATED PROTEIN 4 (CTLA-4)
#23FELINE ANTIBODY LIBRARY
#24MONOCLONAL ANTI-IL-1RACP ANTIBODIES
#25FULLY CANINE ANTI-CANINE PD-1 ANTIBODIES AND USES THEREOF
#26POLYOMAVIRUS NEUTRALIZING ANTIBODIES
#27Anti-thyroglobulin Antibody, Kit and Use Thereof
#28MINI BODIES AS VACCINES FOR HIV
#29FELINE ANTIBODY VARIANTS
#30ANTI-CCR8 AGENTS
#31ANTI-CANINE PD-L1 ANTIBODIES
#32IL-11 HUMANIZED ANTIBODY AND APPLICATION THEREOF
#33PHARMACEUTICAL COMPOSITIONS FOR ANTIBODIES AND MAKING AND USING THE SAME
#34TFR ANTIGEN BINDING PROTEINS AND USES THEREOF
#35ANTIBODIES TO UBIQUITIN C-TERMINAL HYDROLASE L1 (UCH-L1) AND GLIAL FIBRILLARY ACIDIC PROTEIN (GFAP) AND RELATED METHODS
#36FUSION PROTEINS FOR TREATING ATOPIC DERMATITIS
#37TREATMENT OF FIBROSIS
#38PHOSPHO-TAU ANTIBODIES AND METHODS OF USE
#39Phospho-TAU antibodies and methods of use
#40MODIFIED ANTIBODY FOR SITE-SPECIFIC CONJUGATION AND ITS DIAGNOSTIC USE
#41Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
#42TREATMENT OF MEDICATION OVERUSE HEADACHE USING ANTI-CGRP OR ANTI-CGRP-R ANTIBODIES
#43ANTI-B7-H3 MONOCLONAL ANTIBODY AND USE THEREOF
#44ANTI-CD25 ANTIBODY AGENTS
#45ANTI-STAPHYLOCOCCUS ANTIBODIES AND USES THEREOF
#46COMPOSITION OF PIG POLYCLONAL ANTIBODY FOR ITS USE TO TREAT AND/OR PREVENT ANTIBODY-DEPENDENT MACROPHAGE PRO-INFLAMMATORY CYTOKINE RELEASE IN A PASSIVE ANTI-INFECTIOUS IMMUNOTHERAPY
#47ANTIGEN-BINDING MOLECULE PROMOTING DISAPPEARANCE OF ANTIGENS HAVING PLURALITY OF BIOLOGICAL ACTIVITIES
#48DPEP-1 BINDING AGENTS AND METHODS OF USE
#49THERAPEUTIC ANTIBODIES
#50Inhibition of Tau Propagation
#51METHODS OF IMMUNOTHERAPY
#52MODIFIED ANTIBODY COMPOSITIONS, METHODS OF MAKING AND USING THEREOF
#53ANTI-MASP2 ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF AND MEDICAL USE THEREOF
#54POLYPEPTIDES WITH ALTERED BINDING TO NEONATAL FC RECEPTOR (FCRN) AND METHODS OF USE
#55ANTIBODIES BINDING TROP2 AND USES THEREOF
#56METHODS, CELLS & ORGANISMS
#57SYSTEMS AND PROCESSES TO SCREEN FOR SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2) OF 2019 (COVID-19)
#58B7H6 ANTIBODY AND USE THEREOF
#59NS1-BINDING PROTEIN
#60VL ANTIGEN BINDING PROTEINS EXHIBITING DISTINCT BINDING CHARACTERISTICS
#61ANTIBODIES AND ASSAYS FOR CCL14
#62Canine monoclonal antibodies against canine cytotoxic T lymphocyte associated protein 4 (CTLA-4)
#63ANTI-UBIQUITINATION ANTIBODIES AND METHODS OF USE
#64ANTI-COMPLEMENT FACTOR C1Q ANTIBODIES AND USES THEREOF
#65Methods and Compositions for Treating Aging-Associated Impairments with Trefoil Factor Family Member 2 Modulators
#66MUTATIONS IN CANINE ANTIBODY CONSTANT REGIONS
#67MATERIALS AND METHODS FOR PERFORMING HISTOCHEMICAL ASSAYS FOR HUMAN PRO-EPIREGULIN AND AMPHIREGULIN
#68AUTONOMOUS KNOB DOMAIN PEPTIDES
#69THERAPEUTIC ANTIBODY AND USES THEREOF
#70UNGULATE-DERIVED POLYCLONAL IMMUNOGLOBULIN SPECIFIC FOR EGFR AND USES THEREOF
#71CANINE ANTIBODY VARIANTS
#72ASSAYS FOR TIMP2 HAVING IMPROVED PERFORMANCE IN BIOLOGICAL SAMPLES
#73Anti-TIGIT Antibody or Antigen-Binding Fragment Thereof
#74ANTIGEN-BINDING MOLECULES AND USES THEREOF
#75UNGULATE-DERIVED POLYCLONAL IMMUNOGLOBULIN SPECIFIC FOR PD-LI AND USES THEREOF
#76Polyomavirus neutralizing antibodies
#77CANINE ANTIBODY LIBRARIES
#78COMPOSITIONS AND METHODS FOR MUC18 TARGETING
#79CANINIZED ANTIBODIES TO CANINE INTERLEUKIN-31 RECEPTOR ALPHA
#80VECTORIZED FACTOR XII ANTIBODIES AND ADMINISTRATION THEREOF
#81FELINE ANTIBODY VARIANTS
#82FUSION PROTEIN CONTAINING ERYTHROPOIETIN POLYPEPTIDE
#83COORDINATED COEXPRESSION OF THROMBIN
#84Vaccine Compositions and Antibodies For Lyme Disease
#85ANTIBODIES FOR USE IN IMMUNOHISTOCHEMISTRY (IHC) PROTOCOLS TO DIAGNOSE CANCER
#86Canine PD-1-Binding Polypeptides and Uses Thereof
#87NUCLEIC ACIDS ENCODING A POLYPEPTIDE COMPRISING A MODIFIED FC REGION OF A HUMAN IGG1 AND AT LEAST ONE HETEROLOGOUS ANTIGEN
#88ANTI-TRKA ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF, PREPARATION METHOD THEREOF, AND APPLICATION THEREOF
#89ANTI-CTLA-4 ANTIBODY AND USE THEREOF
#90Bispecific Caninized Antibodies and Bispecific Binding Partners for Treating Atopic Dermatitis
#91HUMANIZED ANTIBODIES WITH ULTRALONG COMPLEMENTARY DETERMINING REGIONS
#92CD20 BINDING MOLECULES AND USES THEREOF
#93Bispecific Caninized Antibodies for Treating Atopic Dermatitis
#94FELINE ANTIBODY VARIANTS FOR IMPROVING STABILITY
#95ANTI-NME ANTIBODY AND METHOD OF TREATING CANCER OR CANCER METASTASIS
#96NOVEL DDR1 ANTIBODIES AND USES THEREOF
#97IMMUNOGLOBULINS BINDING HUMAN VGAMMA9VDELTA2 T CELL RECEPTORS
#98CD19 BINDING MOLECULES AND USES THEREOF
#99Antibody and use thereof
#100ANTI- TGFB1,2,3 ANTIBODIES AND THERAPEUTIC USES THEREOF
#101DNABII VACCINES AND ANTIBODIES WITH ENHANCED ACTIVITY
#102AGENT, USES AND METHODS FOR TREATMENT
#103Antibodies to Symmetrically Dimethylated Arginine Analytes and Use Thereof
#104NOVEL DDR1 ANTIBODIES AND USES THEREOF
#105IMMUNOTHERAPEUTIC MODULATION OF AMYLOIDOGENIC DISEASE USING NON-FIBRILLOGENIC, NON-AMYLOIDOGENIC POLYMERIZED PROTEINS AND PEPTIDES
#106SIRPALPHA-TARGETING ANTIBODY OR ANTIGEN BINDING FRAGMENT THEREOF, AND PREPARATION AND APPLICATION THEREOF
#107ANTI-NTB-A ANTIBODIES AND RELATED COMPOSITIONS AND METHODS
#108METHODS OF CONTROLLING ANTIBODY HETEROGENEITY
#109MOTIF-SPECIFIC AND CONTEXT-INDEPENDENT ANTIBODIES THAT SPECIFICALLY BIND TO A SUMOYLATED LYSINE-CONTAINING RESIDUE
#110Antigen binding molecules specific for an anti-CD19 scFV
#111Use of an anti-CCR7 antibody in combination therapies with a BTK inhibitor and/or BCL2- inhibitor for treating hematological malignancies
#112ANTI-8-HYDROXY-2'-DEOXYGUANOSINE ANTIBODY OR ANTIBODY FRAGMENT THEREOF, PRODUCTION METHOD, KIT, MEASURING METHOD, AND DEVICE FOR MEASUREMENT
#113Polyomavirus neutralizing antibodies
#114CHO HOST CELL PROTEIN ASSAY
#115Antibodies for Botulinum Neurotoxins
#116MONOCLONAL ANTIBODIES AND METHODS OF USE
#117CANINIZED ANTIBODIES TO HUMAN CTLA-4
#118Anti-BAG3 antibodies as therapeutic reagent in cardiovascular disease
#119MICE THAT MAKE HEAVY CHAIN ANTIBODIES
#120RESTRICTED IMMUNOGLOBULIN HEAVY CHAIN MICE
#121NON-HUMAN ANIMALS HAVING AN IMMUNOGLOBULIN HEAVY CHAIN VARIABLE REGION THAT INCLUDES AN ENGINEERED DIVERSITY CLUSTER AND USES THEREOF
#122Monoclonal anti-IL-1RAcP antibodies
#123Anti-FXI/FXIa antibody and use thereof
#124Cho host cell protein assay
#125Inhibition of Tau Propagation
#126Anti-CD47 antibody and application thereof
#127METHODS FOR INDUCIBLE EXPRESSION
#128Antibodies for Botulinum Neurotoxins
#129Anti-galactofuranose antibodies for detecting and treating aspergillosis
#130Antibodies with improved stability to intestinal digestion, polynucleotides thereof and methods of use thereof to treat disease
#131Anti-idiotypic antibodies against anti-KLK2 antibodies
#132BISPECIFIC ANTIBODY FOR MEMBRANE CLEARANCE OF TARGET RECEPTORS
#133Variable region sequence of broad-spectrum antibody against clothianidin and dinotefuran and preparation of intact recombinant antibody thereof
#134In vivo methods for selecting peptides that cross the blood brain barrier, related compositions and methods of use
#135ANTI-HIV ANTIBODY AND METHOD FOR PRODUCING SAME
#136Antibodies to symmetrically dimethylated arginine analytes and use thereof
#137TFR-SPECIFIC BINDING MOIETIES AND TRANSCYTOSIS METHOD TO SELECT VNARS THAT CROSS CELLULAR BARRIERS
#138Anti-Siglec-5 antibodies and methods of use thereof
#139Rabbit antibodies to human immunoglobulins G
#140Systems and processes to screen for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) of 2019 (COVID-19)
#141SYSTEMS AND PROCESSES TO SCREEN FOR SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2) OF 2019 (COVID-19)
#142Antibodies to ubiquitin C-terminal hydrolase L1 (UCH-L1) and glial fibrillary acidic protein (GFAP) and related methods
#143Gene Signatures for Determining ICOS Expression
#144THERAPEUTIC CD47 ANTIBODIES
#145Canine antibody libraries
#146Detection of CD-155, the poliovirus receptor
#147Methods and Compositions for Treating Aging-Associated Impairments with Trefoil Factor Family Member 2 Modulators
#148THERAPIES FOR TREATING PROCTITIS WITH POLYCLONAL ANTI-TNFALPHA ANTIBODIES
#149Anti-galactofuranose antibodies for detecting and treating aspergillosis
#150Anti-complement factor C1Q antibodies and uses thereof
#151Agent, uses and methods for treatment
#152Methods and compositions related to soluble monoclonal variable lymphocyte receptors of defined antigen specificity
#153COMPLEMENT C4D ASSAY
#154Compositions and methods for detecting and/or treating inflammation
#155Antibodies to symmetrically dimethylated arginine analytes and use thereof
#156Treatment of fibrosis
#157Anti-lag-3 antibodies and methods of use thereof
#158Bispecific CD16-binding molecules and their use in the treatment of disease
#159Methods and Diagnostics for Cancer Detection and Treatment Monitoring
#160Antibodies to symmetrically dimethylated arginine analytes and use thereof
#161Targeted prevention of maternal to foetal vertical transmission of infection
#162Antibody with non-natural amino acid introduced therein
#163Cyclic compound/peptide comprising an A-beta13-16 peptide and a linker that is covalently coupled to the n-terminus residue and the c-terminus residue of the A-beta13-16 peptide
#164Cyclic compound/peptide comprising an A-beta15-18 peptide and a linker that is covalently coupled to the n-terminus residue and the c-terminus residue of the A-BETA15-18 peptide
#165Materials and methods for performing histochemical assays for human pro-epiregulin and amphiregulin
#166Antibodies and assays for CCL14
#167Immunological targeting of pathological tau proteins
#168Anti-CD25 antibody agents
#169Anti-LAG-3 antibodies and methods of use thereof
#170Methods for treating conditions associated with MASP-2 dependent complement activation
#171Anti-CD25 for tumour specific cell depletion
#172Anti-CD25 for tumour specific cell depletion
#173Compositions comprising cyclic peptides derived from an A-beta peptide
#174Antibodies to symmetrically dimethylated arginine analytes and use thereof
#175IMMUNE MOTIFS IN PRODUCTS FROM DOMESTIC ANIMALS
#176Anti-CD25 for tumour specific cell depletion
#177Anti-CD25 for tumour specific cell depletion
#178Anti-CD25 for tumour specific cell depletion
#179Anti-CD25 antibody agents
#180Anti-CD25 antibody agents
#181Monoclonal anti-IL-1RAcp antibodies
#182Immunogenic Composition
#183HUMAN TNFRSF25 ANTIBODY
#184VL ANTIGEN BINDING PROTEINS EXHIBITING DISTINCT BINDING CHARACTERISTICS
#185Anti-LAG-3 antibodies and methods of use thereof
#186Antigen binding molecules specific for an anti-CD19 scFv
#187CD96 Antibody, Antigen-Binding Fragment and Pharmaceutical use Thereof
#188Compositions and methods for immunotherapy
#189Methods for modulating protein mannosylation profiles using maduramycin, narasin, or salinomycin
#190Antibodies for botulinum neurotoxins
#191Antibodies to symmetrically dimethylated arginine analytes and use thereof
#192Motif-specific and context-independent antibodies that specifically bind to a sumoylated lysine-containing residue
#193TfR selective binding compounds and related methods
#194Method for determining anti-drug antibodies in a minipig sample
#195Transgenic mammals and methods of use thereof
#196Methods for the prevention and treatment of enthesopathy and related disorders
#197Restricted Immunoglobulin Heavy Chain Mice
#198Humanized antibodies with ultralong complementary determining regions
#199Anti-complement factor C1Q antibodies and uses thereof
#200HUMANIZED ANTIBODIES
#201Canine antibody libraries
#202IL-11 antibodies
#203Agent, uses and methods for treatment
#204Polyomavirus neutralizing antibodies
#205POLYVALENT IMMUNOTHERAPEUTICS OF HIGH SPECIFICTY BASED ON MODIFIED ANTIBODIES AND A LYOPHILIZED INJECTABLE FORMULATION HIGHLY SAFE AND EFFECTIVE
#206MODIFIED ANTIBODY CONSTANT REGION
#207Ultralong complementarity determining regions and uses thereof
#208Host cells for use in an inducible coexpression system
#209Antibodies to ubiquitin C-terminal hydrolase L1 (UCH-L1) and glial fibrillary acidic protein (GFAP) and related methods
#210Anti-antibodies and uses thereof
#211Light chain variable regions
#212Semi-synthetic nurse shark VNAR libraries for making and using selective binding compounds
#213Anti-IGF-I receptor antibodies, encoding nucleic acid molecules and methods of using said antibodies
#214ANTIBODY CONJUGATE FOR TREATING AND DETECTING BLADDER CANCER
#215Assays for TIMP2 having improved performance in biological samples
#216Methods for inducible expression of polypeptides
#217BAFF selective binding compounds and related methods
#218Compositions and methods for detecting and/or treating inflammation
#219Synthetic library of specific binding molecules
#220HUMANIZED IMMUNOBINDERS OF CELL-SURFACE ANTIGENS
#221Anti-indoleamine 2,3-dioxygenase 1 antibodies and diagnostic uses thereof
#222ANTI-NTB-A ANTIBODIES AND RELATED COMPOSITIONS AND METHODS
#223Antibodies recognizing genetic variants of NT-proBNP
#224Anti-podocalyxin antibodies and methods of using the same
#225Monoclonal antibodies specific to the plexin-semaphorin-integrin (PSI) domain of RON for drug delivery and its application in cancer therapy
#226Methods, cells and organisms
#227Immunotherapeutic modulation of amyloidogenic disease using non-fibrillogenic, non-amyloidogenic polymerized proteins and peptides
#228DNABII vaccines and antibodies with enhanced activity
#229COMBINATION OF ANTI-CD303 AND ANTI-HER2 ANTIBODIES
#230Anti-CD25 antibody agents
#231Biotin derivatives
#232THROMBIN ANTIBODY, ANTIGEN-BINDING FRAGMENT AND PHARMACEUTICAL USE THEREOF
#233PD-1 antibody, antigen-binding fragment thereof, and medical application thereof
#234Anti-CD25 antibody agents
#235Amyloid beta oligomer specific binding molecule
#236Anti-CD25 antibody agents
#237Methods and compositions for modulaton of transforming growth factor beta-regulated functions
#238Restricted immunoglobulin heavy chain mice
#239Antibody specifically binding to an isolated peptide derived from vimentin or a fragment binding to the peptide
#240DLL3 MODULATORS AND METHODS OF USE
#241Diagnostic anti-PD-L1 antibody and use thereof
#242Anti-complement factor C1q antibodies and uses thereof
#243Cys80 conjugated immunoglobulins
#244Methods and compositions related to soluble monoclonal variable lymphocyte receptors of defined antigen specificity
#245DETERMINATION OF NON-HUMAN MAMMAL TK1 PROTEIN LEVELS
#246Methods for producing antibodies promoting disappearance of antigens having plurality of biological activities
#247In vivo methods for selecting peptides that cross the blood brain barrier, related compositions and methods of use
#248Pharmaceutical composition for preventing or treating cancer and method using thereof
#249TREATMENT OF CANCER WITH ANTI-IL-1 ALPHA ANTIBODIES
#250METHOD FOR INCREASING THE BIOAVAILABILITY OF INHALED COMPOUNDS
#251Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide
#252Method of producing antibody fragment
#253Antibody with non-natural amino acid introduced therein
#254Methods of treatment using activatable anti-EGFR antibodies
#255Monoclonal anti-IL-1RAcP antibodies
#256NUCLEIC ACID AND CORRESPONDING PROTEIN ENTITLED 161P2F10B USEFUL IN TREATMENT AND DETECTION OF CANCER
#257CHO host cell protein assay
#258Compositions and methods for activation of NK cells killing of prostate cancer and breast cancer cells
#259Polyomavirus neutralizing antibodies
#260DLL3 MODULATORS AND METHODS OF USE
#261NOVEL SEZ6 MODULATORS AND METHODS OF USE
#262Treatment of fibrosis with interleukin-11 antibody
#263Polyomavirus neutralizing antibodies
#264Gene signatures for determining ICOS expression
#265Treatment of fibrosis with interleukin-11 receptor alpha antibody
#266Treatment of fibrosis with interleukin-11 receptor alpha antibody
#267Murine anti-NY-ESO-1 T cell receptors
#268Treatment of fibrosis with interleukin-11 antibody
#269Treatment of fibrosis with interleukin-11 receptor alpha antibody
#270Treatment of fibrosis with IL-11 receptor alpha antibody
#271Treatment of fibrosis with Interleukin-11 receptor alpha antibody
#272Treatment of fibrosis with interleukin-11 receptor alpha antibody
#273Treatment of fibrosis with interleukin-11 antibody
#274Treatment of fibrosis with interleukin-11 antibody
#275Treatment of fibrosis with interleukin-11 antibody
#276Treatment of fibrosis with interleukin-11 antibody
#277Methods and Diagnostics for Cancer Detection and Treatment Monitoring
#278Immunoglobulin-like molecules directed against fibronectin-EDA
#279Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide
#280Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide
#281Human TNFRSF25 antibody
#282Method For Making Heteromultimeric Molecules
#283Monocyte modulation and control of tumor metastasis
#284Agent, uses and methods for treatment
#285Method for producing antibodies using ovine B-cells and uses thereof
#286Use of IL-17A and IL-17F cross-reactive monoclonal antibodies for treating inflammatory diseases
#287Vantigen binding proteins exhibiting distinct binding characteristics
#288Treatment of fibrosis
#289Antibody that binds to human programmed death ligand 2 (PD-L2) and uses thereof
#290Anti-mullerian hormone (AMH) neutralizing antibodies and uses thereof
#291Immunoassay of S-adenosylmethionine in personalized medicine and health or cancer evaluation
#292METHODS FOR USING ANTIBODIES AND ANALOGS THEREOF
#293ENHANCED PRODUCTION OF IMMUNOGLOBULINS
#294Notch inhibition in the treatment and prevention of nonalcoholic fatty liver disease
#295Humanized antibodies
#296Immunoglobulin polypeptide fractions from products of domestic animals
#297Compositions and methods for detecting and/or treating inflammation
#298COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY
#299Antibodies for botulinum neurotoxins
#300Anti-GPNMB antibodies and diagnostic uses thereof